TNFRSF17 and plasma cell myeloma: In summary, HRC0202 infusion is safe and effective for the R/R MM patients relapsed or refractory after prior CAR-T infusion, nonetheless, further study and more data of a wide variety of other anti-myeloma therapies are needed for the optimal strategies in patients who have relapsed or refractory following anti-BCMA CAR-T therapy.